Chronic Pulmonary Fungal Infections
Conditions
Interventions
Perfusion therapy group:Transcatheter Amphotericin B
Sponsors
The Second Affiliated Hospital of the Army Medical University of the People's Liberation Army of China
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18–80 years, sex unrestricted. 2) Patients with invasive fungal infection (per the "Diagnostic Criteria and Treatment Principles for Invasive Pulmonary Fungal Infections [Draft]") or chronic pulmonary aspergillosis (including aspergilloma, Aspergillus nodule, chronic cavitary pulmonary aspergillosis, and chronic fibrosing pulmonary aspergillosis). 3) Able to receive standard antifungal therapy and ineligible for surgical curative resection. 4) Patients who have failed initial antifungal therapy. 5) Able to provide written informed consent (ICF) and willing/able to comply with study requirements and the evaluation schedule.
Exclusion criteria
Exclusion criteria: 1) Cases with missing key clinical data, including: absence of pathological or etiological evidence, imaging findings, or incomplete antifungal treatment records; 2) Patients unable to complete the clinical study; 3) Presence of any of the following contraindications to bronchoscopy: active massive hemoptysis; severe hypertension or arrhythmia; recent myocardial infarction or history of unstable angina; severe cardiac or pulmonary dysfunction (except those already receiving cardiopulmonary support); uncorrectable bleeding tendency (e.g., severe coagulation disorder), uremia, or severe pulmonary hypertension; severe superior vena cava syndrome, in which bronchoscopy may precipitate laryngeal edema and serious bleeding; suspected aortic aneurysm; multiple pulmonary bullae; extreme systemic debilitation; 4) Poor patient compliance or violation of trial protocols; 5) Pregnancy; 6) Any other condition that, in the opinion of the investigator, renders the patient unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical domain;Radiological domain ;Mycological domain; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment-Emergent Adverse Events (TEAEs) ; | — |
Countries
China
Contacts
Public ContactZhang Mingzhou
The Second Affiliated Hospital of the Army Medical University of the People's Liberation Army of China
Outcome results
None listed